146 related articles for article (PubMed ID: 16264935)
1. Mechanisms of disease: Inflammatory mediators and cancer prevention.
Mann JR; Backlund MG; DuBois RN
Nat Clin Pract Oncol; 2005 Apr; 2(4):202-10. PubMed ID: 16264935
[TBL] [Abstract][Full Text] [Related]
2. Inflammation and lung carcinogenesis: applying findings in prevention and treatment.
Peebles KA; Lee JM; Mao JT; Hazra S; Reckamp KL; Krysan K; Dohadwala M; Heinrich EL; Walser TC; Cui X; Baratelli FE; Garon E; Sharma S; Dubinett SM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1405-21. PubMed ID: 17944566
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
4. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer.
Hamakawa H; Nakashiro K; Sumida T; Shintani S; Myers JN; Takes RP; Rinaldo A; Ferlito A
Head Neck; 2008 Jun; 30(6):800-9. PubMed ID: 18429007
[TBL] [Abstract][Full Text] [Related]
5. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.
Thomas SM; Bhola NE; Zhang Q; Contrucci SC; Wentzel AL; Freilino ML; Gooding WE; Siegfried JM; Chan DC; Grandis JR
Cancer Res; 2006 Dec; 66(24):11831-9. PubMed ID: 17178880
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between EGFR and TrkB enhances ovarian cancer cell migration and proliferation.
Qiu L; Zhou C; Sun Y; Di W; Scheffler E; Healey S; Kouttab N; Chu W; Wan Y
Int J Oncol; 2006 Oct; 29(4):1003-11. PubMed ID: 16964397
[TBL] [Abstract][Full Text] [Related]
7. Energy balance, physical activity, and cancer risk.
Fair AM; Montgomery K
Methods Mol Biol; 2009; 472():57-88. PubMed ID: 19107429
[TBL] [Abstract][Full Text] [Related]
8. Increased cyclooxygenase-2 expression associated with inflammatory cellular infiltration in elderly patients with vulvar cancer.
Lee TS; Jeon YT; Kim JW; Won JK; Park NH; Park IA; Juhnn YS; Kang SB; Lee HP; Song YS
Ann N Y Acad Sci; 2007 Jan; 1095():143-53. PubMed ID: 17404027
[TBL] [Abstract][Full Text] [Related]
9. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
10. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S; Schiff R
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
[TBL] [Abstract][Full Text] [Related]
11. Inflammation: gearing the journey to cancer.
Kundu JK; Surh YJ
Mutat Res; 2008; 659(1-2):15-30. PubMed ID: 18485806
[TBL] [Abstract][Full Text] [Related]
12. Rational bases for the development of EGFR inhibitors for cancer treatment.
Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
[TBL] [Abstract][Full Text] [Related]
13. Use of novel second-line targeted therapies in non-small cell lung cancer.
Massarelli E; Herbst RS
Semin Oncol; 2006 Feb; 33(1 Suppl 1):S9-16. PubMed ID: 16472704
[TBL] [Abstract][Full Text] [Related]
14. Targeting multiple signal pathways by chemopreventive agents for cancer prevention and therapy.
Sarkar FH; Li YW
Acta Pharmacol Sin; 2007 Sep; 28(9):1305-15. PubMed ID: 17723164
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor biology in head and neck cancer.
Kalyankrishna S; Grandis JR
J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
[TBL] [Abstract][Full Text] [Related]
16. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
Maione P; Gridelli C; Troiani T; Ciardiello F
Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
[TBL] [Abstract][Full Text] [Related]
17. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway.
MacLaine NJ; Wood MD; Holder JC; Rees RW; Southgate J
Mol Cancer Res; 2008 Jan; 6(1):53-63. PubMed ID: 18234962
[TBL] [Abstract][Full Text] [Related]
19. Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer.
Lanza-Jacoby S; Burd R; Rosato FE; McGuire K; Little J; Nougbilly N; Miller S
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6161-9. PubMed ID: 17062693
[TBL] [Abstract][Full Text] [Related]
20. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
Narayanan BA; Reddy BS; Bosland MC; Nargi D; Horton L; Randolph C; Narayanan NK
Clin Cancer Res; 2007 Oct; 13(19):5965-73. PubMed ID: 17908994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
